A highly pathogenic porcine reproductive and respiratory syndrome virus candidate vaccine based on Japanese encephalitis virus replicon system

PeerJ

article

Pingsheng Hu¹  Xiaoming Chen¹  Lihong Huang¹  Shukai Liu¹  Fuyu Zang¹  Jinchao Xing¹  Youyue Zhang¹  Jiaqi Liang¹  Guihong Zhang¹  Ming Liao¹  Wenbao Qi¹ 

[1] National and Regional Joint Engineering Laboratory for Medicament of Zoonoses Prevention and Control, College of Veterinary Medicine, South China Agricultural University;Key Laboratory of Zoonoses, Key Laboratory of Animal Vaccine Development, Ministry of Agriculture;Key Laboratory of Zoonoses Prevention and Control of Guangdong Province, Ministry of Agriculture

关键词: JEV replicon;    HP-PRRSV;    Vaccine;   

DOI  :  10.7717/peerj.3514

学科分类：社会科学、人文和艺术（综合）

来源: Inra

【 摘 要 】

In the swine industry, porcine reproductive and respiratory syndrome (PRRS) is a highly contagious disease which causes heavy economic losses worldwide. Effective prevention and disease control is an important issue. In this study, we described the construction of a Japanese encephalitis virus (JEV) DNA-based replicon with a cytomegalovirus (CMV) promoter based on the genome of Japanese encephalitis live vaccine virus SA14-14-2, which is capable of offering a potentially novel way to develop and produce vaccines against a major pathogen of global health. This JEV DNA-based replicon contains a large deletion in the structural genes (C-prM-E). A PRRSV GP5/M was inserted into the deletion position of JEV DNA-based replicons to develop a chimeric replicon vaccine candidate for PRRSV. The results showed that BALB/c mice models with the replicon vaccines pJEV-REP-G-2A-M-IRES and pJEV-REP-G-2A-M stimulated antibody responses and induced a cellular immune response. Analysis of ELSA data showed that vaccination with the replicon vaccine expressing GP5/M induced a better antibodies response than traditional DNA vaccines. Therefore, the results suggested that this ectopic expression system based on JEV DNA-based replicons may represent a useful molecular platform for various biological applications, and the JEV DNA-based replicons expressing GP5/M can be further developed into a novel, safe vaccine candidate for PRRS.

【 授权许可】

CC BY